Gilead stock has been one of the biggest biotech stocks to watch this year, especially after its recent fall from triple-digit highs… The Gilead Sciences Inc. (Nasdaq: GILD) stock price hit a 2016 high of $102.29 less than a month ago on April …
Let's delve into the value metrics of Gilead Sciences (GILD) and determine whether it is a good value investment right now. Let's delve into the value metrics of Gilead Sciences (GILD) and determine whether it is a good value investment right now.
It's been a less-than-stellar year for biotech blue chip Gilead Sciences (NASDAQ: GILD). The company's stock has been mired in a pretty steady downtrend since June 2015, and, over the trailing 12 months, it's off an unsightly 26%. Mind …
Gilead Sciences (ticker: GILD) shareholders have endured a steady downward drift since the stock peaked at its all-time high of $119.59 back in mid-2015. On Friday, Barclays analyst Geoff Meacham released a new research note in which …
CHICAGO, Sept. 1, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHK, F, GE, GILD, …
Gilead Sciences Inc : Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week objective in two phase 3B studies .Plans to submit data for presentation at scientific conferences in 2016..
Gilead Sciences Inc. GILD just released their second quarter fiscal 2016 earnings results, posting earnings of $3.03 per share and revenue of $7.776 billion. Currently, GILD has a Zacks Rank #2 (Buy), but it is subject to change following …
Gilead Sciences has been a dream stock for long-term investors. Anyone who was smart enough to get in at the IPO in 1992 and hold the stock until today are sitting on a gain of around 17,000%! That kind of performance is simply …
Gilead Sciences Inc. (Nasdaq: GILD) stock hit a 52-week high of $92.97 this morning (Thursday) after the company crushed earnings estimates last night. At that price, GILD stock has climbed 3% from yesterday's close. In yesterday's …